Researchers have developed a potential COVID-19 vaccine that can be given intranasally. If successful results are reported, the vaccine could make administration simpler and reduce the costs of vaccination programs. According to a study published in Cell Press , researchers have developed a chimpanzee adenoviral vaccine encoding stabilized S spike protein (ChAd-SARS-CoV-2-S) along with mice expressing the human angiotensin-converting enzyme 2 receptors (hACE2) and SARS-CoV-2.
It was further observed that immunization with ChAd-SARS-CoV-2-S results in the development of neutralizing antibodies and antigen-specific CD8+ T cell responses . While a single intramuscular immunization with ChAd-SARS-CoV-2-S protects against SARS-CoV-2 infection and inflammation in the lungs, the intranasal delivery of ChAd-SARS-CoV-2-S induces mucosal immunity . Superior protection, which may promote…
